LY 3849889
Alternative Names: LY-3849889Latest Information Update: 29 Dec 2021
Price :
$50 *
At a glance
- Originator Dicerna Pharmaceuticals
- Developer Dicerna Pharmaceuticals; Eli Lilly and Company
- Class Cardiovascular therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk
- 25 Feb 2021 Dicerna Pharmaceuticals and Eli Lilly plan to submit IND application in Q1 2022 (Dicerna Pharmaceuticals pipeline, February 2021)